
    
      The primary objectives of this study are to identify the maximum tolerated dose(MTD) and to
      evaluate safety of atiprimod in patients with advanced cancer.

      The secondary objectives of this study are 1) to measure the pharmacokinetics of atiprimod
      and 2) to evaluate the efficacy of atiprimod treatment in patients with advanced cancers and
      3) to compare the pharmacokinetics of atiprimod tablets and capsules at the starting dose,
      with the intent of switching to capsules for the dose escalation if the capsules pose no
      safety issues.
    
  